


RECEIVED
DEC 21 2001
#4
TO CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re Application of : R. MATALON et al.

Serial No.: 09/965,807

Group Art Unit: 1653

Filed: October 1, 2001

Examiner: G. Bugaisky

For: APARTOACYLASE GENE, PROTEIN, AND METHODS OF SCREENING FOR MUTATIONS ASSOCIATED WITH CANAVAN DISEASE

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98

Assistant Commissioner for Patents
Washington, D. C. 20231

Sir:

CITED MATERIALS

Applicant(s) hereby disclose the information listed in the attached form PTO-1449.

- Copies of materials listed but not attached were cited in parent application Serial No. 08/128,020; see 37 C.F.R. § 1.98(d).
- Copies of materials listed but not attached were cited in an International Search Report dated ____; receipt of any International Search Report and copies of references were confirmed by the PCT International Division of the U.S. PTO in the Notice of Acceptance mailed ____.

ADDITIONAL INFORMATION

- All listed materials are in the English language; see 37 C.F.R. § 1.98.
- Other:
 - The reference(s) in the English-language is (are) indicated by commercial search services to correspond to the reference(s), respectively.
 - No translation or English-language equivalent of the reference(s) is known; an English-language abstract therefore is provided.
 - An English-language search report or an equivalent paper from a foreign patent office translated into English in pertinent part in connection with a counterpart foreign application, is provided indicating the relevance of the reference(s).

FEES

- No fee is required for this Information Disclosure Statement because:
 - This Information Disclosure Statement is being filed within three months of the filing date of a national application (other than a CPA) under § 1.53(d) or within 3 months of the date of entry of the national stage under § 1.491 in an international application;
 - This Information Disclosure Statement is being filed before the mailing of a first action on the merits;
 - This Information Disclosure Statement is being filed after a first action on the merits but before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311, or an action that closes prosecution in the application, and is accompanied by a certification below.
 - This Information Disclosure Statement is filed under 37 C.F.R. § 1.97(i).
- A fee is required for this Information Disclosure Statement:
 - This Information Disclosure Statement is being filed after a first action on the merits but before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311 or an action that closes prosecution, and is accompanied by the fee set forth in §1.17(p).
 - This Information Disclosure Statement is being filed after the mailing date of a final rejection or a notice of allowance under § 1.311 or an action that closes prosecution, but before the payment of the issue fee, and is accompanied by the fee set forth in § 1.17(p) and a certification below.


CERTIFICATION

- Each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR § 1.56(c), more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

If appropriate, attached is a check in the amount of \$_____. However, the Commissioner is hereby authorized to charge fees under 37 CFR § 1.16 and § 1.17 which may be required to facilitate this filing, or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,



Nancy J. Axelrod
Registration No. 44,014
Patent Agent

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
Arlington Courthouse Plaza 1
2200 Clarendon Blvd. Suite 1400
Arlington, Virginia 22201
Telephone: (703) 243-6333
Facsimile: (703) 243-6410

Date: December 18, 2001

DEC 21 2001

TECH CENTER 1600/2900
PTO/SB/08A (08-09)

•TO/SB/08A (08-00)

Please type a plus sign (+) inside this box → +

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
responsible for a collection of information on how to obtain a valid QM registration.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

<i>Complete if Known</i>	
Application Number	09/965,807
Filing Date	October 1, 2001
First Named Inventor	Matalon et al.
Group Art Unit	1653
Examiner Name	TBA
Attorney Docket Number	SHUTT 1-C1



U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED

DEC 21 2001

TECH CENTER 1600/2900

PTO/SB/08A (08-00)

Please type a plus sign (+) inside this box → +

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

2

of

2

Complete if Known

Application Number	09/965,807
Filing Date	October 1, 2001
First Named Inventor	Matalon et al.
Group Art Unit	1653
Examiner Name	TBA
Attorney Docket Number	SHUTT 1-C1

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Leong et al., <i>Methods in Enzymology</i> , 78: 87-101 (1981)	
		Kaul et al., <i>J. Neurochem.</i> 56 (1) 129-135 (1991)	
		Matalon et al., <i>Am. J. Med. Genet.</i> 29: 463-471 (1988)	
		Adamo et al., <i>J. Neurochem.</i> 28 (4) 739-44 (1977)	
		Hagenfeldt et al., <i>J. Inherit. Metab. Dis.</i> 10 (2) 135-141 (1987)	

Examiner Signature		Date Considered
--------------------	--	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.